Substance use & addiction journal最新文献

{"title":"Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study.","authors":"Orrin D Ware, David A Fiellin, Mark P McGovern","doi":"10.1177/29767342261445244","DOIUrl":"10.1177/29767342261445244","url":null,"abstract":"<p><strong>Background: </strong>This study examined specific mental health diagnoses groupings among patients admitted to specialty addiction treatment in the United States from 2006 to 2022.</p><p><strong>Methods: </strong>Joinpoint regression was used to examine annual data from the publicly available Treatment Episode Data Set - Admissions. Sample selection criteria included having a primary substance listed and any of the following conditions: (a) anxiety disorders, (b) bipolar disorders, (c) depressive disorders, and (d) schizophrenia and other psychotic disorders.</p><p><strong>Results: </strong>Prior to sample selection, across the full dataset of 31 152 649, cases with anxiety disorders accounted for 0.1%, bipolar disorders accounted for 0.3%, depressive disorders accounted for 0.4%, and schizophrenia and other psychotic disorders accounted for 0.1%. The total sample size was N = 224 051 with: (a) 13% for anxiety disorders (n = 29 111), (b) 30.3% for bipolar disorders (n = 67 926), (c) 43.4% for depressive disorders (n = 97 293), and (d) 13.3% for schizophrenia and other psychotic disorders (n = 29 721). Count data identified significant decreases including the following: 12.29% from 2008 to 2022 among the bipolar disorder group, 16.69% from 2019 to 2022 among the depressive disorder group, and 6.96% from 2006 to 2022 among the schizophrenia and other psychotic disorders group.</p><p><strong>Conclusion: </strong>This study has important implications for future research and clinical care related to co-occurring mental health and substance use disorders. Its findings demonstrate the need for further studies to examine how addiction treatment facilities are screening for and recording mental health disorder diagnoses. Future research is needed to clarify the prevalence of specific mental health diagnoses in the addiction treatment setting, including diagnoses such as anorexia nervosa and generalized anxiety disorder. This research would help determine specific treatment needs by using epidemiological data to provide a snapshot of the prevalence of these co-occurring conditions.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1090-1097"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Addiction Scholarship: Transparency, Accountability, and Disclosure in Research and Publishing.","authors":"Adam J Gordon, Mark Bounthavong, Colleen Corte, Elizabeth Siantz, Khadejah F Mahmoud, Deborah S Finnell, Taneisha Scheuermann, Evans F Kyei, Jessica J Wyse, Elizabeth M Oliva, Marianne Pugatch, Rebekah S Halmo, Sarah Rosenwohl-Mack, Sarah J Marks, Babalola Faseru","doi":"10.1177/29767342261471638","DOIUrl":"10.1177/29767342261471638","url":null,"abstract":"<p><p>Artificial intelligence (AI) is embedded in addiction scholarship, not only as a methodological tool in research but also as a tool for manuscript preparation. In addiction research and clinical care, AI is already used to analyze data and support clinical decision-making. In parallel, AI tools are increasingly used to summarize literature, revise prose, generate outlines, draft text, and assist with interpretation and presentation of findings. These developments create an urgent need for addiction journals to clarify how AI use should be governed and disclosed. In this editorial, we argue for a principled, proportionate framework for AI disclosure grounded in materiality. We distinguish AI used in the conduct of research from AI used in manuscript preparation and propose a practical taxonomy of assistive, intermediate, and generative AI mapped onto 6 escalating levels of involvement. We identify intermediate AI as a key governance challenge because it may appear to provide editorial assistance while materially shaping scholarly content. We argue that disclosure should be required when AI materially contributes to the conduct of research or to the intellectual content, interpretation, argument, or presentation of a manuscript, while routine low-risk assistive uses should not require disclosure. Transparent governance, organized around materiality rather than specific technologies, is the appropriate response to AI in addiction publishing.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"941-952"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Language Processing to Identify Substance Use in Electronic Health Records: A Scoping Review.","authors":"Chidimma Doris Azubuike, Ahmed Farrag, Kimia Zandbiglari, Ahmed Soliman, Celina Bagchi, Fatemeh Mehrabi, Lauren E Adkins, Masoud Rouhizadeh, Amie Goodin","doi":"10.1177/29767342261463377","DOIUrl":"10.1177/29767342261463377","url":null,"abstract":"<p><strong>Background: </strong>This scoping review aimed to characterize natural language processing (NLP) techniques deployed for identifying substance use in electronic health records (EHRs) and to compare the performance of these techniques by substance type.</p><p><strong>Methods: </strong>We conducted a systematic search of PubMed, the Cochrane Library, Embase, Web of Science, ACM Digital Library, IEEE Xplore, and Scopus for peer-reviewed original research published in English. Studies were eligible if they applied NLP to identify non-prescription or problematic substance use in EHRs, provided full-text access, and reported quantitative performance metrics.</p><p><strong>Results: </strong>A total of 86 studies met the inclusion criteria. NLP-identified substance use included tobacco (n = 42), alcohol (n = 26), non-prescription opioids (n = 30), cannabinoids (n = 9), stimulants (n = 6), and polysubstance use and/or other drugs (n = 16). NLP techniques included rule-based (n = 46), conventional machine learning (n = 39), deep learning (n = 17), and large language/transformer-based models (n = 22), with some studies applying multiple techniques. Annotation guidelines were available for 30 studies, and only 22 published their codes. Most studies reported performance metrics exceeding 0.80.</p><p><strong>Conclusions: </strong>Tobacco, opioids, and alcohol were the most frequently identified substances, whereas stimulants and cannabinoids were markedly underrepresented. Across the reviewed literature, transparency and reproducibility were limited, with few studies publishing code or detailed model specifications. Nevertheless, reported performance metrics were generally high. NLP techniques showed high performance in identifying tobacco, opioids, and alcohol use in EHRs, but stimulants and cannabinoids remain underrepresented. Transparency and reproducibility remain limited, underscoring the need for routine sharing of code, datasets, and model specifications.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1273-1287"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering the Term \"Patient\" in Alcohol and Other Drug Treatment Settings.","authors":"Bethany T Nixon, Peter J Kelly, Alison K Beck, Isabella Ingram, Laura D Robinson","doi":"10.1177/29767342261460407","DOIUrl":"10.1177/29767342261460407","url":null,"abstract":"<p><p>Language plays a central role in shaping healthcare culture, relationships, and expectations. Within alcohol and other drug (AOD) treatment, the term patient remains widely used, including within patient-reported outcome and experience measures (PROMs and PREMs). Yet in a treatment context that increasingly emphasizes collaboration, autonomy, and recovery-oriented care, the continued use of the patient deserves closer scrutiny. This commentary argues that the patient is not a neutral descriptor in AOD settings. The term may shape how people experience services, how they understand their role in treatment, and their willingness to engage with care. Where it is experienced as passive, hierarchical, or inconsistent with the relational and collaborative nature of AOD treatment, it may undermine engagement and potentially influence outcomes. Terminology may also influence how clinicians perceive and interact with the people they support. These concerns are especially relevant in PROMs and PREMs, where patient-based language sits uneasily alongside the person-centered values these measures are intended to reflect and promote. Reframing these tools as <i>person-reported</i> outcome and experience measures would represent a simple and practical step toward greater alignment. This commentary was further informed through consultation with a Consumer Advisory Group, whose lived and living experience perspectives highlighted the importance of language that conveys dignity, agency, and respect within treatment settings. Their input reinforced the need for terminology that reflects collaborative and recovery-oriented models of care. Although current evidence is insufficient to justify a single universally preferred alternative, and further research is needed to better understand how terminology influences engagement and experiences of care, more person-centered language practices are both possible and necessary. These include referring to individuals by name and directly asking how they wish to be addressed. Greater attention to language offers a practical opportunity to better align AOD services with the collaborative and recovery-oriented values they increasingly seek to embody.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"990-994"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rural-Urban Inequalities in Lifetime Tobacco Consumption Among Middle-Aged and Older Adults in India: A Decomposition Analysis Using Survey-Weighted National Data.","authors":"Pritam Halder, Divya Sharma, Sukhmeen Kaur, Sonu Goel, Pradeep Sharma, Tanvi Kiran","doi":"10.1177/29767342261436545","DOIUrl":"10.1177/29767342261436545","url":null,"abstract":"<p><p>IntroductionTobacco consumption was leading global risk factor for mortality in 2023. This study aimed to assess rural-urban inequalities in lifetime tobacco consumption among Indian adults aged 45 years and above, alongside socioeconomic inequalities.</p><p><strong>Methods: </strong>Data from the Longitudinal Ageing Study in India (2017-18, Wave-1) were analyzed, focusing on participants aged >45 years. Weighted prevalence estimates and chi-squared tests were utilized to compare tobacco use across groups. Socioeconomic disparities were examined using the concentration index, and multivariate decomposition analysis identified the contribution of socioeconomic, demographic, health-related, and behavioral factors to rural-urban differences in tobacco consumption.</p><p><strong>Results: </strong>Overall, 36.78% of middle-aged and older adults (45 years and above) reported tobacco use, with a rural-urban gap of 17.72%. Smokeless tobacco (19.88%) was more prevalent than smoking (13.92%), and 2.98% used both forms. The rural-urban gap was greater for smokeless tobacco (9.54%) than for smoking (6.06%). The Northeast region showed the highest prevalence of any tobacco use (54.29%), smokeless (36.65%), and dual use (5.88%), while the North had the highest smoking rates (24.56%). Socioeconomic disparities were more pronounced in urban areas, with higher tobacco use among poorer groups. Compositional factors explained 58% of the rural-urban difference, primarily driven by education (24.74%), region (17.43%), and alcohol use (11.30%). This indicates that if urban and rural areas had the same educational characteristics, regional distribution and prevalence of alcohol consumption, the difference tobacco consumption would decrease by 53.47%.</p><p><strong>Conclusion: </strong>Tobacco consumption is more prevalent in rural and economically disadvantaged populations. Strengthening National Tobacco Control Program (NTCP) implementation, particularly in rural and Northeastern regions, and addressing socioeconomic determinants are crucial to reducing tobacco use and narrowing rural-urban disparities.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1047-1059"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Neurocognitive Symptoms With Opioid Overdose Events Among Patients on Long-Term Opioid Therapy.","authors":"Casey León, Minhee L Sung, Joel I Reisman, Weisong Liu, Robert D Kerns, Kirsha S Gordon, Avijit Mitra, Sunjae Kwon, Hong Yu, William C Becker, Wenjun Li","doi":"10.1177/29767342261443858","DOIUrl":"10.1177/29767342261443858","url":null,"abstract":"<p><strong>Background: </strong>Neurocognitive symptoms (NCS)-including difficulties with attention, memory, and executive functioning-are common among patients receiving long-term opioid therapy (LTOT) for pain. Although cognitive impairment may influence safety, its relationship to opioid overdose has not been evaluated at scale. This study assessed whether NCS are associated with opioid overdose among Veterans prescribed LTOT.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using national Veterans Health Administration (VHA) data. Patients prescribed LTOT (≥90 days of continuous opioid prescriptions) in 2018 were included. NCS during LTOT episodes were measured via diagnostic codes and natural language processing. The primary outcome was fatal and nonfatal opioid overdose, identified through ICD codes. A Cox proportional hazards model estimated the association between NCS and overdose events, adjusting for demographics, co-occurring diagnoses, VHA visits, opioid dose, and LTOT duration.</p><p><strong>Results: </strong>The opioid overdose risk for patients with NCS, compared with those without, during LTOT receipt was higher, risk ratio (95% CI) = 5.80 (3.99-8.41). Cox regression analysis showed that adjusted hazard ratio (aHR) of opioid overdose was significantly higher for patients with NCS during LTOT (aHR 2.54 [2.10-3.06]). Factors associated with increased overdose risk included black race, presence of a substance use disorder, cardiovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, opioid dose >50 mg morphine equivalent daily dose, and LTOT duration of 12 months or fewer. Sensitivity analyses yielded similar results. Age between 45 and 64 (vs 75 and older) was associated with decreased overdose risk.</p><p><strong>Conclusion: </strong>Neurocognitive symptoms are independently associated with increased risk of opioid overdose among Veterans receiving LTOT. Incorporating cognitive screening into opioid safety assessments may help identify individuals at heightened risk and inform tailored risk mitigation strategies.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1108-1117"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uptake and Retention on Prescribed Psychostimulants for Harm Reduction: A Canadian Cohort Study.","authors":"Paxton Bach, JinCheol Choi, Wing Yin Mok, M-J Milloy, Kora DeBeck, Thomas Kerr, Kanna Hayashi","doi":"10.1177/29767342261443853","DOIUrl":"10.1177/29767342261443853","url":null,"abstract":"<p><strong>Background: </strong>Methamphetamine use is on the rise in North America and is a growing contributor to the ongoing overdose crisis. Prescription psychostimulants have been available for patients with stimulant use disorder through a provincial harm reduction policy in British Columbia, Canada, since 2020, however, there is little data to inform the uptake of and retention in this intervention in the real-world.</p><p><strong>Methods: </strong>Data from 3 harmonised prospective cohorts of people who use drugs in Vancouver, Canada, were examined for information on uptake, prescribing patterns, and retention on prescribed psychostimulants provided for the purposes of harm reduction among people who use non-prescribed stimulants. We used a general estimating equations model to examine factors associated with their use.</p><p><strong>Results: </strong>Among 1005 participants interviewed between 2020 and 2022, 79 (7.9%) received at least one prescription for a psychostimulant as a harm reduction intervention. Daily methamphetamine use and being engaged in some form of addiction treatment were both associated with increased odds of receiving a prescription while later calendar year and age were associated with decreased odds (all <i>P</i> < .05). Dextroamphetamine was the most common prescription (70%), followed by methylphenidate (29%). Retention on prescribed psychostimulants was low with only 23% of those receiving a prescription still on the medication at 6-month follow-up.</p><p><strong>Conclusion: </strong>We observed a low and declining uptake of psychostimulant prescriptions provided for harm reduction purposes during this period, along with poor retention in treatment. These results suggest that further research should investigate factors to improve uptake and engagement of this medication among people who use stimulants, including patient suitability and dosing patterns.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1191-1197"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proactive Tele-Outreach to Increase Adoption of Medications for Opioid Use Disorder in a Large Health Care System.","authors":"David Lawrence, Pushpa V Raja, Cristian D Yanes, Jia Y Fan, Isabella Morton, Manuel A Celedon, Jesse D Barglow, Katherine C Bailey, Larissa J Mooney, Adam J Gordon, Sonya E Gabrielian","doi":"10.1177/29767342261442456","DOIUrl":"10.1177/29767342261442456","url":null,"abstract":"<p><strong>Background: </strong>Medications for opioid use disorder (MOUD) are shown to improve quality of life while reducing risk for overdose and death among people with OUD. The Veterans Health Administration has supported numerous efforts to increase MOUD availability, but a treatment gap persists: among Veterans with OUD, half do not receive MOUD, and over 5000 died from overdose between 2016 and 2021. To improve MOUD adoption in a large VA health system, we developed a care model to identify and proactively engage Veterans with untreated OUD.</p><p><strong>Methods: </strong>The Virtual Outreach Low-Threshold MOUD care initiative (VOLT), a multi-faceted implementation bundle to support MOUD adoption, had 3 core elements: (1) an electronic health record-powered case-finder to identify individuals with untreated OUD and recent OUD-related clinical events (new OUD diagnosis, nonfatal opioid-involved overdose, acute care encounter for OUD, or referral to residential treatment for OUD), (2) case-finder result reconciliation by a physician champion, and (3) proactive tele-outreach to validated cases of untreated OUD by an MOUD prescriber.</p><p><strong>Results: </strong>The Case-Finder identified 526 encounters over a 2-year evaluation period. Most were either flagged for an inaccurate OUD diagnosis corrected by the physician champion (163, 31%), or validated as appropriate for tele-outreach (107, 20%). Of tele-outreach cases, 67 (63%) were contacted, and 37 (55%) were deemed MOUD-eligible. Of these, 28 (76%) initiated MOUD, all opting for buprenorphine. Retention on MOUD was 71% at 3 months and 57% at 6 months. The proportion of health system Veterans with OUD receiving MOUD increased from 44% pre- to 54% post-implementation.</p><p><strong>Conclusion: </strong>VOLT engaged Veterans with untreated OUD and recent OUD-related clinical events in buprenorphine care with high 3- and 6-month retention and was associated with a 10-percentage point increase in system-wide MOUD adoption. This novel care model may complement existing efforts to close the MOUD treatment gap.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1080-1089"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared Medical Appointments for Substance Use Disorders: A Systematic Review.","authors":"Kush Sehgal, Ana Carolina Leal, Leticia Mara Dos Santos Barbetta, Neil Nero, Akhil Anand","doi":"10.1177/29767342261457248","DOIUrl":"10.1177/29767342261457248","url":null,"abstract":"<p><strong>Background: </strong>Shared medical appointments (SMAs) integrate group-based clinical care with individual medical management and are increasingly used in the treatment of substance use disorders (SUDs) to improve access, engagement, and care coordination. However, their use, outcomes, and implementation in SUD care have not been systematically synthesized.</p><p><strong>Methods: </strong>We conducted a systematic review registered with PROSPERO (CRD42025639504). MEDLINE, Embase, PsycINFO, Scopus, and Cochrane Central were searched from database inception through September 2025. Randomized controlled trials, observational studies, and qualitative studies examining SMAs among adults with SUDs were included. Outcomes of interest included treatment engagement and retention, substance use outcomes, mental health and patient-reported outcomes, and implementation characteristics. Study quality was assessed across quantitative and qualitative designs, and findings were synthesized descriptively.</p><p><strong>Results: </strong>Fourteen studies, representing approximately 578 participants, met inclusion criteria. Twelve studies focused exclusively on opioid use disorder, 1 included both alcohol and opioid use disorders, and 1 did not specify substance type. Treatment retention was reported in 6 studies, with a median 6-month retention of 72.9%. Three studies reported reductions in substance use outcomes, and 2 reported improvements in depression or anxiety. Qualitative studies consistently described high patient satisfaction, peer support, and shared accountability. Implementation studies demonstrated feasibility across diverse outpatient settings, with substantial heterogeneity across study designs and outcomes.</p><p><strong>Conclusions: </strong>SMAs appear feasible and acceptable for addiction care and may support treatment retention and patient experience. Evidence remains heterogeneous and largely observational, highlighting the need for rigorous comparative studies to better define effectiveness and implementation.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"1288-1296"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148440649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptability, Appropriateness, and Feasibility of Implementing the Locus-of-Hope Enhancement Program: Perspectives of Substance Use Disorder Treatment Providers.","authors":"Sixtus Dane A Ramos, Angela Lorraine P Cunanan, Paul Angelo S Arcega, Allan B I Bernardo","doi":"10.1177/29767342261490083","DOIUrl":"https://doi.org/10.1177/29767342261490083","url":null,"abstract":"<p><strong>Background: </strong>Positive psychological interventions have been introduced in substance use disorder (SUD) treatment, yet the possibility of multisite implementation of programs that cater to hope as a positive cognitive disposition based on the perspectives of SUD treatment providers are yet to be evaluated. Using the implementation outcomes framework, the current study investigated the acceptability, appropriateness, and feasibility of a positive psychological intervention grounded on hope.</p><p><strong>Methods: </strong>In the current study, 5 professional and 4 peer SUD treatment providers underwent focus group discussions and provided their perspectives on future multisite implementation of the Locus-of-Hope Enhancement Program (LEAP), a positive intervention that fosters hope, well-being, and recovery for people with SUD.</p><p><strong>Results: </strong>Participants reported that LEAP is an acceptable, appropriate, and feasible positive intervention for SUD that can be embedded in a therapeutic community program. Participants also identified some of LEAP's limitations and recommended improvements for the intervention.</p><p><strong>Conclusions: </strong>The results offer valuable knowledge on LEAP's implementation outcomes that can guide future multisite implementation studies on positive psychological interventions that promote well-being and recovery for individuals with SUD.</p>","PeriodicalId":516535,"journal":{"name":"Substance use & addiction journal","volume":" ","pages":"29767342261490083"},"PeriodicalIF":2.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149121924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}